Top News

Eisai and BioGen Alzheimer’s Drug Shows Promising Results in Phase III Study

December 01, 2022

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

AstraZeneca Acquires Neogene Therapeutics for $320 Million

November 30, 2022

AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.

FDA Approves $3.5 Million Hemophilia B Gene Therapy

November 28, 2022

CSL’s Hemgenix (etranacogene dezaparvovec) will cost approximately $3.5 million, making it the most expensive single-use medicine in the United States.

Merck Announces $1.35 Billion Acquisition of Imago BioSciences

November 28, 2022

Merck will purchase Imago BioSciences, a biotechnology company focused on bone marrow disorders, for approximately $1.35 billion.

Regeneron and Cytomx Announce $2 Billion Oncology Collaboration

November 22, 2022

The collaboration will see the companies develop investigational next-generation bispecific immunotherapies for cancer.

Sanofi and Insilico Medicine Ink $1.2 Billion Drug Development Deal

November 16, 2022

The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.

J&J to Acquire Abiomed for $16.6 Billion

November 02, 2022

Johnson & Johnson’s acquisition of Abiomed, a provider of heart pump technologies, is designed to bolster their position in the medical technology sector.

CPHI 2022 Award Winners Announced

November 02, 2022

The winners of the 2022 CPHI Excellence in Pharma Awards were announced on Nov. 1, 2022 at an awards ceremony in Frankfurt, Germany.

Gilead and MacroGenics Enter $1.7 Billion Oncology Collaboration

October 19, 2022

Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.

Merck and Moderna Enter $250 Million Cancer Vaccine Partnership

October 14, 2022

Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.